Core Viewpoint - The company, Heng Rui Medicine, has received approval from the National Medical Products Administration for clinical trials of five new drug candidates, indicating a significant advancement in its oncology pipeline [1][2][3]. Group 1: Drug Candidates Overview - HRS-6208 is a novel, highly selective small molecule inhibitor that effectively suppresses phosphorylation activation of its target, impacting cell cycle and transcriptional activity to inhibit tumor cell proliferation. No similar products have been approved in the market, with a cumulative R&D investment of approximately 38.14 million yuan [1]. - HRS-6209 is a selective CDK4 inhibitor that induces tumor cell arrest in the G1 phase, aimed at treating advanced malignant solid tumors. It shows improved selectivity over CDK6/cyclinD3 pathways compared to existing CDK4/6 inhibitors, with a cumulative R&D investment of about 119.85 million yuan [2]. - HRS-8080 is a novel oral selective estrogen receptor degrader (SERD) designed to degrade ER and inhibit its activity, targeting ER-positive and ER-mutated breast cancer. The cumulative R&D investment for this project is around 198.70 million yuan [2]. - HRS-5041 is a new, highly selective AR PROTAC molecule intended for prostate cancer treatment, demonstrating significant degradation of wild-type and most mutant AR proteins, with a cumulative R&D investment of approximately 92.66 million yuan [3]. - HRS-1358 is a targeted estrogen receptor (ER) degrading PROTAC molecule that can overcome resistance due to target protein mutations, with a cumulative R&D investment of about 96.01 million yuan [3].